A series of large-scale randomized controlled trials (RCTs) demonstrated that SGLT2i use reduced the risk of kidney disease progression in patients with and without diabetes ( post hoc analysis of SUSTAIN6 and PIONEER6 demonstrated that semaglutide slowed the eGFR decline in T2D patients with a high risk of CVD ( With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome in the main analysis of RECAP study ( post hoc analysis, the SGLT2i-preceding group had a slower rate of eGFR decline in comparison to the GLP1Ra-preceding group, and multiple regression analysis identified the preceding of SGLT2i as an independent and significant factor of change in eGFR decline
The SURMOUNT-5 cardiovascular outcomes trial continues to enroll at Louisiana sites [13]
The complex regulatory capacity of miRNAs, whereby a single species can influence entire signaling pathways while being influenced by metabolic alterations, provides a unique opportunity to develop novel intervention strategies for DN that address multiple aspects of its pathogenesis simultaneously [156, 157]
Understanding brand-name Mounjaro costs helps put compounded pricing in perspective
Our walk-in model means you can come in on your own schedule, without booking an appointment weeks ahead
Sulistyo, H., Kurniawan, D
